Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Recruiting Not applicable Interventional

Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

NCT07751029
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions
Interventions
Haelan 951
Dietary Supplement
Lead sponsor
Spectrum Clinical Research, LLC
Network
Eligibility
45 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 12:51 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Single Arm Post-marketing Study of SC20 Colonoscope

NCT02279836
View directory record Official record
Conditions
Gentle Colonoscopy
Interventions
SC20 Colonoscope
Device
Lead sponsor
Invendo Medical GmbH
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 16, 2026, 12:51 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

NCT01487239
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 12:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Function and Uterine Fibroids

NCT02123069
View directory record Official record
Conditions
Leiomyoma
Interventions
Brachial artery catheter, Acetylcholine, Nitroprusside, Norepinephrine, Nitroprusside and phenylephrine
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

NCT04714554
View directory record Official record
Conditions
Healthy
Interventions
Relugolix/E2/NETA FDC, Relugolix, Erythromycin
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 16, 2026, 12:51 AM EDT
Terminated Phase 1 Interventional

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

NCT00102622
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Intraperitoneal tgDCC-E1A, Paclitaxel
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

NCT02210325
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

NCT05891262
View directory record Official record
Conditions
Healthy Female Volunteers
Interventions
BMS-986196, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase IC Study of Safety and PK of SQ109 300mg Daily

NCT01358162
View directory record Official record
Conditions
Tuberculosis
Interventions
Placebo, SQ109
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 16, 2026, 12:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Lyrette: Renewing Continence Objective and Subjective Efficacy Study

NCT01455779
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Lyrette
Device
Lead sponsor
Verathon
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
6
States / cities
Murrieta, California • Arlington Heights, Illinois • Oak Lawn, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Not applicable Interventional

Mobile Phone Technology to Increase Genetic Counseling

NCT02877862
View directory record Official record
Conditions
Ovarian Cancer
Interventions
mAGIC app
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

NCT03551288
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SUVN-911
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

NCT04650542
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
HBI-3000, Paroxetine
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 16, 2026, 12:51 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 4 Interventional

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610
View directory record Official record
Conditions
HIV Infection
Interventions
Nelfinavir mesylate, 625 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

NCT01161979
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide, Zonegran
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

NCT01053520
View directory record Official record
Conditions
Healthy Female Subjects
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Warfarin and PA21

NCT01477424
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
PA21, Warfarin
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 4 Interventional

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

NCT06173661
View directory record Official record
Conditions
Migraine, Menstrual Migraine, Menstrually Related Migraine
Interventions
Fremanezumab, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325
View directory record Official record
Conditions
Hyperuricemia, Gout, Qt Interval, Variation in
Interventions
LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Women In Steady Exercise Research (WISER) Survivor Trial

NCT01515124
View directory record Official record
Conditions
Lymphedema
Interventions
Exercise Intervention, Weight Loss Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 80 Years · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 16, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359
View directory record Official record
Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
CF-301, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Lenexa, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 16, 2026, 12:51 AM EDT